Completed PHASE3 INTERVENTIONAL 2-arm NCT01229774

Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty

Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty, a Prospective, Double Blind, Phase III Study

Sponsor: Merck Sharp & Dohme LLC

Conditions Arthroplasties Hip Replacement Coxarthrosis Perioperative Blood Loss

Interventions Diclofenac Etoricoxib

Updated 6 times since 2017 Last updated: Sep 12, 2014 Started: Feb 28, 2011 Primary completion: Aug 31, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01229774, this PHASE3 trial focuses on Arthroplasties Hip Replacement and Coxarthrosis and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jun 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
University of Regensburg

Data source: University of Regensburg

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bad Abbach, Germany